EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Creation of an ustekinumab external control arm for Crohn’s disease using electronic health records data: A pilot study

Vivek A Rudrapatna iD, Yao-Wen Cheng, Colin Feuille iD, Arman Mosenia, Jonathan Shih, Yongmei Shi, Olivia Roberson, Benjamin Rubin, Atul J Butte, Uma Mahadevan, Nicholas Skomrock, Ngozi Erondu und 8 weitere

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0282267 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Vivek A Rudrapatna und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, CA, United States of America. Hauptthemen laut MEDLINE: Ustekinumab, Crohn Disease. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences, UCSF Bakar Computational Health Sciences Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Randomized trials are the gold-standard for clinical evidence generation, but they can sometimes be limited by infeasibility and unclear generalizability to real-world practice. External control arm (ECA) studies may help address this evidence gaps by constructing retrospective cohorts that closely emulate prospective ones. Experience in constructing these outside the context of rare diseases or cancer is limited. We piloted an approach for developing an ECA in Crohn’s disease using electronic health records (EHR) data.

Methods

We queried EHR databases and manually screened records at the University of California, San Francisco to identify patients meeting the eligibility criteria of TRIDENT, a recently completed interventional trial involving an ustekinumab reference arm. We defined timepoints to balance missing data and bias. We compared imputation models by their impacts on cohort membership and outcomes. We assessed the accuracy of algorithmic data curation against manual review. Lastly, we assessed disease activity following treatment with ustekinumab.

Results

Screening identified 183 patients. 30% of the cohort had missing baseline data. Nonetheless, cohort membership and outcomes were robust to the method of imputation. Algorithms for ascertaining non-symptom-based elements of disease activity using structured data were accurate against manual review. The cohort consisted of 56 patients, exceeding planned enrollment in TRIDENT. 34% of the cohort was in steroid-free remission at week 24.

Conclusion

We piloted an approach for creating an ECA in Crohn’s disease from EHR data by using a combination of informatics and manual methods. However, our study reveals significant missing data when standard-of-care clinical data are repurposed. More work will be needed to improve the alignment of trial design with typical patterns of clinical practice, and thereby enable a future of more robust ECAs in chronic diseases like Crohn’s disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

UstekinumabCrohn DiseaseHumansPilot ProjectsElectronic Health RecordsProspective StudiesRetrospective Studies

Substanzen

Ustekinumab

Autor:innen und Institutionen

  • Division of Gastroenterology, Department of Medicine, University of California, San Francisco, San Francisco, CA, United States of America.
  • Bakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, United States of America.
  • School of Medicine, University of California, San Francisco, San Francisco, CA, United States of America.
  • Department of Neurology, University of California, San Francisco, San Francisco, CA, United States of America.
  • Department of Pediatrics, University of California, San Francisco, San Francisco, CA, United States of America.
  • Janssen Research and Development, Spring House, PA, United States of America.

ORCID-Profile: Vivek A Rudrapatna, Colin Feuille

Förderung

  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences
  • UCSF Bakar Computational Health Sciences Institute
  • Janssen Research and Development

Zitieren

APA

Rudrapatna, V. A., Cheng, Y. W., Feuille, C., Mosenia, A., Shih, J., Shi, Y., Roberson, O., Rubin, B., Butte, A. J., Mahadevan, U., Skomrock, N., Erondu, N., Chehoud, C., Rahim, S., Apfel, D., Curran, M., Khan, N. S., O'Brien, C., Terry, N., & Martini, B. D. (2023). Creation of an ustekinumab external control arm for Crohn’s disease using electronic health records data: A pilot study. PLOS ONE. https://doi.org/10.1371/journal.pone.0282267

Vancouver

Rudrapatna VA, Cheng YW, Feuille C, Mosenia A, Shih J, Shi Y, et al. Creation of an ustekinumab external control arm for Crohn’s disease using electronic health records data: A pilot study. PLOS ONE. 2023. doi:10.1371/journal.pone.0282267

BibTeX
@article{Rudrapatna2023,
  author = {Rudrapatna, Vivek A and Cheng, Yao-Wen and Feuille, Colin and Mosenia, Arman and Shih, Jonathan and Shi, Yongmei and Roberson, Olivia and Rubin, Benjamin and Butte, Atul J and Mahadevan, Uma and Skomrock, Nicholas and Erondu, Ngozi and Chehoud, Christel and Rahim, Saquib and Apfel, David and Curran, Mark and Khan, Najat S and O'Brien, Christopher and Terry, Natalie and Martini, Benjamin D},
  title = {Creation of an ustekinumab external control arm for Crohn’s disease using electronic health records data: A pilot study},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0282267}
}
Kostenlos starten →